Skip to main content
. 2022 Dec 5;11(12):12289. doi: 10.1002/jev2.12289

FIGURE 3.

FIGURE 3

Antitumour recurrence effect of BDVs‐triggered cancer immunotherapy in the surgical bed of B16F10‐luc model. (a) Schematic illustration of BDVs‐triggered cancer vaccine in an incomplete‐surgery B16F10‐luc tumour model. (b) In vivo bioluminescence images of the B16F10‐luc tumour‐bearing mice (n = 5). (c) Single tumour volume of each mouse in different groups. (d) Tumour growth curves in B16F10‐luc model (n = 7), Error bar, mean ± s.e.m.. (e) Tumour weights in different treatment groups (n = 7), Error bar, mean ± s.d.. (f) Survival curves in different groups (n = 10) (#1) Gel‐PBS, (#2) Gel‐Blank BDVs, (#3) Gel‐Normal‐M33‐M47 BDVs, (#4) Gel‐Mutation‐M33‐M47 BDVs, (#5) aPD‐1 (anti‐PD‐1 antibody), (#6) Gel‐Mutation‐M33‐M47 BDVs + aPD‐1. NS: no significant, *P < 0.05, **P < 0.01, ***P < 0.001. One‐way ANOVA with Tukey post‐hoc tests (d, e) or the Long‐Rank (Mantel‐Cox) test (f)